Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHARE II: short versus standard amoxicillin for lower-limb erysipelas
2024-515306-61-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of amoxicillin in erysipelas (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rate of complete remission at day 12 ± 2 days. Planned start Sep 2026; status: authorised.
02
Drugs
amoxicillin
03
Conditions
erysipelas
Beyond the preview
Go deeper on 2024-515306-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515306-61-00.